Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates

被引:147
|
作者
Zhao, Robert Y. [1 ]
Wilhelm, Sharon D. [1 ]
Audette, Charlene [1 ]
Jones, Gregory [1 ]
Leece, Barbara A. [1 ]
Lazar, Alexandru C. [1 ]
Goldmacher, Victor S. [1 ]
Singh, Rajeeva [1 ]
Kovtun, Yelena [1 ]
Widdison, Wayne C. [1 ]
Lambert, John M. [1 ]
Chari, Ravi V. J. [1 ]
机构
[1] ImmunoGen Inc, Waltham, MA 02451 USA
关键词
CALICHEAMICIN CONJUGATE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; CANCER; CELLS; DOXORUBICIN; ACID; TRANSPORTERS; CHEMOTHERAPY; SPECIFICITY;
D O I
10.1021/jm2002958
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive N-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo.
引用
收藏
页码:3606 / 3623
页数:18
相关论文
共 50 条
  • [41] Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings
    Taplin, Sarah
    Vashisht, Kapil
    Walles, Markus
    Calise, David
    Kluwe, William
    Bouchard, Page
    Johnson, Robert
    JOURNAL OF APPLIED TOXICOLOGY, 2018, 38 (05) : 600 - 615
  • [42] Cleavable linkers in antibody-drug conjugates
    Bargh, Jonathan D.
    Isidro-Llobet, Albert
    Parker, Jeremy S.
    Spring, David R.
    CHEMICAL SOCIETY REVIEWS, 2019, 48 (16) : 4361 - 4374
  • [43] Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck
    Ponte, Jose F.
    Setiady, Yulius Y.
    Dong, Ling
    Skaletskaya, Anna
    Carrigan, Christina N.
    Anderson-Villaluz, Alfred
    Lutz, Robert J.
    Pinkas, Jan
    CANCER RESEARCH, 2013, 73 (08)
  • [44] Design, Synthesis, and invitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates
    Chen, Bo
    Gianolio, Diego A.
    Stefano, James E.
    Manning, Charlene M.
    Gregory, Richard C.
    Busch, Michelle M.
    Brondyk, William H.
    Miller, Robert J.
    Dhal, Pradeep K.
    CHEMMEDCHEM, 2018, 13 (08) : 790 - 794
  • [45] IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy
    Ab, Olga
    Bartle, Laura M.
    Rui, Lingyun
    Coccia, Jennifer
    Johnson, Holly A.
    Whiteman, Kathleen R.
    Kellogg, Brenda
    Clancy, Lauren
    Sun, Xiuxia
    Goldmacher, Victor S.
    CANCER RESEARCH, 2011, 71
  • [46] Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers
    Mueller, Barbara M.
    Wrasidlo, Wolf A.
    Reisfeld, Ralph A.
    BIOCONJUGATE CHEMISTRY, 1990, 1 (05) : 325 - 330
  • [47] Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
    Setiady, Yulius Y.
    Park, Peter U.
    Ponte, Jose F.
    Dong, Ling
    Skaletskaya, Anna
    Coccia, Jennifer A.
    Hong, Erica
    Clancy, Lauren
    Rui, Lingyun
    Pinkas, Jan
    Lutz, Robert J.
    Lambert, John M.
    Chittenden, Thomas D.
    CANCER RESEARCH, 2013, 73 (08)
  • [48] Antibody and linker selection for the anti-CD37 antibody-maytansinoid conjugate IMGN529 for the treatment of B-cell malignancies
    Park, Peter U.
    Yi, Yong
    Li, Min
    Chicklas, Sharon
    Lai, Katharine C.
    Mayo, Michele F.
    Coccia, Jennifer A.
    Deckert, Jutta
    Pinkas, Jan
    Chittenden, Thomas D.
    CANCER RESEARCH, 2011, 71
  • [49] A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates
    Fleming, MS
    Zhang, W
    Lambert, JM
    Amphlett, G
    ANALYTICAL BIOCHEMISTRY, 2005, 340 (02) : 272 - 278
  • [50] Peroxide-cleavable linkers for antibody-drug conjugates
    Ashman, Nicola
    Bargh, Jonathan D.
    Walsh, Stephen J.
    Greenwood, Ryan D.
    Tiberghien, Arnaud
    Carroll, Jason S.
    Spring, David R.
    CHEMICAL COMMUNICATIONS, 2023, 59 (13) : 1841 - 1844